USPTO Examiner ELENISTE PIERRE PAUL - Art Unit 1622

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18660829THIADIAZOLYL DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS AND USES THEREOFMay 2024April 2025Allow1111NoNo
18498894OXAZOLE COMPOUND CRYSTALOctober 2023May 2025Abandon1810NoNo
18223290METHODS OF REDUCING DISEASE FLARESJuly 2023September 2024Abandon1410NoNo
18060027BCKDK INHIBITORS AND/OR DEGRADERSNovember 2022June 2025Allow3121NoNo
17938824PIGMENTED SPOT FORMATION INHIBITOR, INCREASED MELANOSOME PHAGOCYTOSIS INHIBITOR, AND EPIDERMAL DIFFERENTIATION POTENCY IMPROVEROctober 2022March 2025Abandon2921NoNo
17936821TOPICAL PHARMACEUTICAL COMPOSITION IN GEL FORM COMPRISING AT LEAST AMITRIPTYLINE FOR USE IN THE TREATMENT OF NEUROPATHIC PHANTOM LIMB PAINSeptember 2022January 2025Abandon2820NoNo
17933881METHODS OF TREATING METABOLIC DISORDERSSeptember 2022January 2025Abandon2820NoNo
17896332TRIS(ALKOXYCARBONYLAMINO)TRIAZINE COMPOSITION, COATING COMPOSITION COMPRISING THE SAME AND MANUFACTURING METHOD THEREOFAugust 2022June 2025Allow3440YesNo
17821943PROPOFOL COMPOSITIONS AND METHODS OF USEAugust 2022May 2024Abandon2111NoNo
17888600SPIROHEPTANYL HYDANTOINS AS ROCK INHIBITORSAugust 2022March 2024Allow1910NoNo
17811731BICYCLIC COMPOUNDS AS ANDROGEN RECEPTOR MODULATORSJuly 2022January 2024Allow1911YesNo
17811790CD38 MODULATORS AND METHODS OF USE THEREOFJuly 2022May 2025Abandon3421NoNo
17858562METHOD OF PREPARING PH-SENSITIVE CONTROLLED-RELEASE EMULSION HYDROGELJuly 2022June 2025Abandon3640YesNo
17787680SALT FORM AND CRYSTAL FORM OF MUTANT IDH1 INHIBITOR AND PREPARATION METHOD THEREFORJune 2022May 2025Allow3501NoNo
17824478TOPICAL OTIC, OPHTHALMIC, AND NASAL CORTICOSTEROID FORMULATIONSMay 2022February 2024Allow2120NoNo
17707975MULTIFUNCTIONAL WOOD PRESERVATIVE COMPOSITION AND WOOD PRESERVATION TREATMENT METHOD USING THE SAMEMarch 2022February 2025Abandon3430NoNo
17692153COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF PROTEIN KINASESMarch 2022December 2023Abandon2121NoNo
17668239COMPOSITIONS AND METHODS FOR MONITORING, DIAGNOSIS, PROGNOSIS, DETECTION, AND TREATMENT OF CANCERFebruary 2022January 2025Allow3531YesNo
17665190POLYOXAZOLINE-LIPID CONJUGATES AND LIPID NANOPARTICLES AND PHARMACEUTICAL COMPOSITIONS INCLUDING SAMEFebruary 2022October 2024Allow3321NoNo
17473967WATER-SOLUBLE CURCUMIN LIQUID AND PREPARATION METHOD AND APPLICATION THEREOFSeptember 2021September 2024Allow3610YesNo
17426277USE OF P1P DERIVATIVES AS THERAPEUTIC AGENT FOR SEPSISJuly 2021May 2025Abandon4610NoNo
17425505PRE-NATAL BETA-CRYPTOXANTHIN BENEFITS CHILDRENJuly 2021December 2024Abandon4110NoNo
17311403CRYSTALLINE FORMS OF 1-(1,2-DIMETHYLPROPYL)-N-ETHYL-5-METHYL-N-PYRIDAZIN-4-YL-PYRAZOLE-4-CARBOXAMIDEJune 2021June 2025Allow4820NoNo
17299648PYRAZOLOPYRIMIDINE PDE9 INHIBITORSJune 2021June 2025Allow4821NoNo
17242530PREVENTION OF AGE RELATED CLONAL HEMATOPOIESIS AND DISEASES ASSOCIATED THEREWITHApril 2021December 2024Abandon4310NoNo
172865913-(1H-PYRAZOL-4-YL)PYRIDINE ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTORApril 2021January 2024Allow3310NoNo
17221866HIGH-PERFORMING METAL-FREE PRIMARY EXPLOSIVEApril 2021November 2023Allow3110NoNo
17221552METHODS FOR THE TREATMENT OF BLADDER CANCERApril 2021February 2025Abandon4711NoNo
17280633HETEROCYCLIC COMPOUNDMarch 2021December 2023Allow3300NoNo
17206498METHODS AND COMPOSITIONS FOR TREATMENT OF PERIPHERAL NEUROPATHIESMarch 2021September 2024Abandon4220YesNo
17277702BORONIC ACID POLYMERS AND METHODS OF USEMarch 2021April 2025Abandon4920NoNo
17277156CANCER COMBINATION THERAPY USING QUINOLINE CARBOXAMIDE DERIVATIVEMarch 2021May 2024Abandon3810NoNo
17270770USE OF CICLOPIROX FOR INHIBITING HBV CORE ASSEMBLYFebruary 2021March 2025Abandon4930NoNo
17170690AMINOPYRIDINE DERIVATIVES AND THEIR USE AS SELECTIVE ALK-2 INHIBITORSFebruary 2021January 2024Allow3630NoYes
17266929METHOD OF DIAGNOSING AND TREATING ALZHEIMER DISEASE USING PLASMA TAU LEVEL IN CONJUNCTION WITH BETA-AMYLOID LEVEL AS DIAGNOSTIC INDEXFebruary 2021February 2025Abandon4920NoNo
17265290INSECTICIDAL COMBINATIONSFebruary 2021November 2024Allow4521NoNo
17263016PYRIDONE A2R ANTAGONISTSJanuary 2021April 2024Allow3820YesNo
17047529PHARMACEUTICAL COMBINATION PRODUCTS COMPRISING A HISTONE DEACETYLASE (HDAC) INHIBITOR AND A TLR7 AGONIST AND/OR TLR8 AGONIST FOR THE TREATMENT OF CANCEROctober 2020December 2024Abandon5030NoNo
17044322QUINOLINE OR QUINAZOLINE COMPOUND AND APPLICATION THEREOFSeptember 2020September 2024Abandon4840NoNo
16891427HYDROCHLORIDE SALT FORM FOR EZH2 INHIBITIONJune 2020November 2024Abandon5441NoNo
16256522PROCESSES TO PRODUCE BRIVARACETAMJanuary 2019October 2024Allow60111YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner ELENISTE, PIERRE PAUL.

Strategic Value of Filing an Appeal

Total Appeal Filings
1
Allowed After Appeal Filing
1
(100.0%)
Not Allowed After Appeal Filing
0
(0.0%)
Filing Benefit Percentile
95.4%
Higher than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 100.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the top 25% across the USPTO, indicating that filing appeals is particularly effective here. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Strategic Recommendations

Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Examiner ELENISTE, PIERRE PAUL - Prosecution Strategy Guide

Executive Summary

Examiner ELENISTE, PIERRE PAUL works in Art Unit 1622 and has examined 40 patent applications in our dataset. With an allowance rate of 45.0%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 36 months.

Allowance Patterns

Examiner ELENISTE, PIERRE PAUL's allowance rate of 45.0% places them in the 5% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by ELENISTE, PIERRE PAUL receive 2.12 office actions before reaching final disposition. This places the examiner in the 71% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by ELENISTE, PIERRE PAUL is 36 months. This places the examiner in the 16% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +37.5% benefit to allowance rate for applications examined by ELENISTE, PIERRE PAUL. This interview benefit is in the 87% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 11.8% of applications are subsequently allowed. This success rate is in the 3% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 23.5% of cases where such amendments are filed. This entry rate is in the 23% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 200.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 92% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 84% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 57.1% are granted (fully or in part). This grant rate is in the 72% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 0% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for RCE after final rejection: This examiner rarely enters after-final amendments. Budget for an RCE in your prosecution strategy if you receive a final rejection.
  • Request pre-appeal conferences: PACs are highly effective with this examiner. Before filing a full appeal brief, request a PAC to potentially resolve issues without full PTAB review.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.